131 related articles for article (PubMed ID: 2111049)
21. Study of endothelial t-PA and vWf in normal subjects and in von Willebrand's disease.
Wieczorek I; Ludlam CA; MacGregor IR
Blood Coagul Fibrinolysis; 1994 Jun; 5(3):329-34. PubMed ID: 8075304
[TBL] [Abstract][Full Text] [Related]
22. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
24. Additive effect of dDAVP and standard heparin in increasing plasma t-PA.
Agnelli G; Levi M; Cosmi B; ten Cate JW; Nenci GG
Thromb Haemost; 1989 Jun; 61(3):507-10. PubMed ID: 2508260
[TBL] [Abstract][Full Text] [Related]
25. Tissue plasminogen activator release in chronic venous hypertension due to heart failure.
Keber I; Keber D; Stegnar M; Vene N
Thromb Haemost; 1992 Sep; 68(3):321-4. PubMed ID: 1440498
[TBL] [Abstract][Full Text] [Related]
26. A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men.
Prowse CV; Farrugia A; Boulton FE; Tucker J; Ludlam CA; McLaren M; Belch JJ; Prentice CR; Dawes J; MacGregor IR
Thromb Haemost; 1984 Feb; 51(1):110-4. PubMed ID: 6426076
[TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
Pedersen OD; Gram J; Jespersen J
Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
[TBL] [Abstract][Full Text] [Related]
28. Increase of tissue plasminogen activator in limbs during venous occlusion: a simple haemodynamic model.
Keber D; Blinc A; Fettich J
Thromb Haemost; 1990 Nov; 64(3):433-7. PubMed ID: 2128974
[TBL] [Abstract][Full Text] [Related]
29. Fibrinolytic response in normal subjects to venous occlusion and DDAVP infusion.
Cugno M; Uziel L; Fabrizi I; Bottasso B; Maggiolini F; Agostoni A
Thromb Res; 1989 Dec; 56(5):625-34. PubMed ID: 2516662
[TBL] [Abstract][Full Text] [Related]
30. [Influence of aging and circadian fluctuation of fibrinolytic factors to the responses of these factors during venous occlusion test in healthy subjects].
Motohashi F; Masui Y; Kamogawa A; Hayashi T; Miyake F; Murayama M; Sugai J; Yasumuro Y
Rinsho Byori; 1992 Feb; 40(2):172-8. PubMed ID: 1583790
[TBL] [Abstract][Full Text] [Related]
31. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
[TBL] [Abstract][Full Text] [Related]
32. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
[TBL] [Abstract][Full Text] [Related]
33. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm.
Wall U; Jern S; Tengborn L; Jern C
Blood; 1998 Jan; 91(2):529-37. PubMed ID: 9427706
[TBL] [Abstract][Full Text] [Related]
34. [Disorders of the liberation of tissue-type plasminogen activator (t-PA) from the venous wall as a cause for recurrent thromboses].
Hach-Wunderle V; Scharrer I
Vasa Suppl; 1993; 39():5-10. PubMed ID: 8322122
[TBL] [Abstract][Full Text] [Related]
35. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
[TBL] [Abstract][Full Text] [Related]
36. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress.
Jern C; Selin L; Jern S
Thromb Haemost; 1994 Aug; 72(2):285-91. PubMed ID: 7831666
[TBL] [Abstract][Full Text] [Related]
37. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma.
Huisman LG; van Griensven JM; Kluft C
Thromb Haemost; 1995 Mar; 73(3):466-71. PubMed ID: 7667830
[TBL] [Abstract][Full Text] [Related]
38. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Kluft C; Jie AF; Rijken DC; Verheijen JH
Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
[TBL] [Abstract][Full Text] [Related]
39. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
40. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
